Articles tagged "Hepatitis C"

2022 American Transplant Congress
Renal Transplants In Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Using Two Weeks Of DAA Prophylaxis (Rehanna – 2)
N. M. Desai¹, S. Leung¹, J. Motter¹, F. Naqvi², N. Bair¹, B. Barnaba², D. Warren¹, D. Segev¹, C. Durand²
¹Surgery, Johns Hopkins University, Baltimore, MD, ²Medicine, Johns Hopkins University, Baltimore, MD
*Purpose: To mitigate the organ shortage and underutilization of hepatitis C-infected deceased donor (HCV D+) organs, we evaluated the use of HCV D+ kidneys in…
2022 American Transplant Congress
Hypothermic Pulsatile Flush of Hepatitis C Virus (HCV) RNA Positive Kidney Reduces Viral Load
A. Jain¹, W. Greene²
¹Transplant Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, ²Dept. of Pathology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA
*Purpose: Does Hypothermic pulsatile flush of hepatitis C virus (HCV) RNA positive kidney reduce the viral load?*Methods: Unutilized, HCV RNA-positive deceased donor kidneys were obtained…
2022 American Transplant Congress
Kidney Transplant Alone Recipients with Advanced Liver Disease Have Similar Outcomes to Those without Advanced Liver Disease
R. R. Nathani, S. M. Rutledge, C. Villarroel, R. Shapiro, G. Y. Im
Icahn School of Medicine at Mount Sinai, New York, NY
*Purpose: The prevalence of concomitant liver disease (CLD) in patients with ESRD is reported to be 7-40%. Safety of kidney transplant alone (KTA) in those…
2022 American Transplant Congress
Compliance with OPTN Infectious Disease Testing
L. Irwin
Massachusetts General Hospital, Boston, MA
*Purpose: Effective 3/1/21 OPTN policy requires all transplant recipients to have pre-transplant and post-transplant infectious disease testing performed at specific intervals: upon admission and prior…
2022 American Transplant Congress
Cost-Effectiveness of Transplanting Hepatitis C Donor Hearts Into Hepatitis C Uninfected Recipients
A. R. Gandhi¹, A. E. Woolley², L. R. Baden², M. M. Givertz², M. L. Jones¹, J. Kim³, H. R. Mallidi², M. R. Mehra², A. M. Neilan¹
¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA
*Purpose: To examine the clinical impact and cost-effectiveness of hepatitis C viremic (HCV+) heart organ donation in the United States.*Methods: We used a microsimulation model…
2022 American Transplant Congress
Twelve Month Outcomes of Kidney Transplantation from Hepatitis C Viremic Deceased Donors to Aviremic Recipients
L. A. Binari, R. C. Forbes, S. Rega, I. D. Feurer, A. Dreher, S. Shawar, H. Schaefer, D. Shaffer, B. P. Concepcion
Vanderbilt University Medical Center, Nashville, TN
*Purpose: The utilization of Hepatitis C viremic (HCV+) deceased donor kidneys for uninfected recipients allows for increased opportunities for organ transplantation. Initial studies have indicated…
2022 American Transplant Congress
Impact of Glecaprevir/Pibrentasvir on Tacrolimus Concentration in Solid Organ Transplant Recipients with or without Triazole Antifungal Therapy
D. Abraham¹, A. Feist², N. Law¹, S. Aslam¹, V. Nguyen¹
¹University of California San Diego Health, San Diego, CA, ²University of California San Diego, San Diego, CA
*Purpose: Provide guidance on tacrolimus (TAC) dose adjustments during glecaprevir/pibrentasvir (GLE/PIB) initiation and discontinuation in patients on triazole antifungals by comparing changes in TAC concentration-dose…
2022 American Transplant Congress
Long-Term Follow Up of Solid Organ Transplantation Using Hepatitis C Virus Positive Donor for Hepatitis C Virus Negative Recipients
H. Sogawa¹, I. Lee², K. Okumura³, R. Bodin⁴, D. C. Wolf⁴, B. Partiula⁴, A. Dhand⁴, M. Kai⁵, S. Ohira⁵, R. Misawa¹, G. Veillette⁶, D. John¹, S. Nishida⁷, T. Diflo⁶
¹Division of Intra-abdominal Organ Transplant, Department of Surgery, Westchester Medical Center/ New York Medical College, Valhalla, NY, ²Department of Surgery, Westchester Medical Center/ New York Medical College, Valhalla, NY, ³Surgery, Westchester Medical Center/New York Medical College, Valhalla, NY, ⁴Department of Medicine, Westchester Medical Center/ New York Medical College, Valhalla, NY, ⁵Cardiothoracic Surgery, Westchester Medical Center/ New York Medical College, Valhalla, NY, ⁶Westchester Medical Center, Valhalla, NY, ⁷Westchester Medical Center/ New York Medical College, Valhalla, NY
*Purpose: To determine the effects of transplanting an HCV + solid organ to an uninfected patient who is on the transplant waiting list. Outcomes include…
2022 American Transplant Congress
The Oncological Influences of Pre- and Post-Transplant Sustained Viral Response in Liver Transplant for Hepatocellular Carcinoma
K. Sasaki¹, S. Kimura², K. Tomiyama³, Y. Bekki⁴, M. Murray³, P. Huang³, M. Fruscione², A. Moro⁵, C. Kwon⁶
¹Stanford University, Stanford, CA, ²Massachusetts General Hospital, Boston, MA, ³University of Rochester, Rochester, NY, ⁴Mount Sinai Medical Center, New York, NY, ⁵University of South Florida, Tampa, FL, ⁶Cleveland Clinic, Cleveland, OH
*Purpose: Chronic hepatitis C infection (HCV) is one of the most common causes of hepatocellular carcinoma. After emerging direct-acting agents (DAA), the success rate of…
2022 American Transplant Congress
Transplantation of Hepatitis C Viremic Donor Organs to Hepatitis C Nonviremic Recipients: A Retrospective Review
M. Leick, M. Blaha, M. Henry
Nebraska Medicine, Omaha, NE
*Purpose: The advent of combination direct-acting antiviral (DAA) agents has improved the ability to treat hepatitis C virus (HCV) infections. As a result, utilization of…